greeksoup/ stock research
Stock research / United States / Funds / Great Point Partners LLC

Great Point Partners LLC

CIK 1281446 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

Great Point Partners LLC reported 37 US-listed holdings worth $424.4 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Vor Biopharma Inc. (7.4%), Abivax SA (6.4%) and Vera Therapeutics Inc. (6.1%). Against the quarter before, it opened 11 positions, added to 7, trimmed 9 and sold out of 13.

Reported holdings$424.4M+4.0% on Q1 2026
Positions37-2 on Q1 2026
The largest ten53.6%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
OpenedAdded toHeldTrimmed
VOR7.4%ABVX6.4%VERA6.1%ZURA5.9%ALMS5.7%SLGL4.8%DFTX4.7%ANNX4.7%ORKA4.1%MLTX3.9%SGMT3.7%CTNM3.6%IMMX3.1%CLYM23 more32.9%

The 14 largest of its 37 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $331.4 million in 29 positions$331MQ3 24Q4 2024: $212.2 million in 26 positions$212MQ4 24Q1 2025: $184.0 million in 31 positions$184MQ1 25Q2 2025: $153.8 million in 26 positions$154MQ2 25Q3 2025: $239.5 million in 28 positions$240MQ3 25Q4 2025: $308.4 million in 29 positions$308MQ4 25Q1 2026: $408.3 million in 39 positions$408MQ1 26Q2 2026: $424.4 million in 37 positions$424MQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What its reported holdings returned

Held through each quarter, the holdings it reported returned +100.7% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.

Its reported holdingsThe S&P 500
4590135180Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Its holdings +100.7%S&P 500 +30.2%

Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.

What it did on the quarter

Opened 11Added 7Held 10Trimmed 9Sold out 13
Opened: 11Added: 7Held: 10Trimmed: 9Sold out: 13

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 11

  1. Abivax SA ABVX$27.2 million
  2. Definium Therapeutics Inc. DFTX$20.0 million
  3. Sagimet Biosciences Inc. SGMT$15.7 million
  4. Inflarx NV IFRX$6.8 million
  5. Jatt II Acquisition Corp. JATT$5.7 million
  6. Altimmune, Inc. (alt) ALT$5.3 million
  7. Amanat Acquisition Corp. AMAN$5.1 million
  8. Scynexis Inc. SCYX$3.8 million

and 3 more in the table below

Added to 7

  1. Vera Therapeutics Inc. VERA+401,488 shares · +201%
  2. Immix Biopharma Inc. IMMX+927,642 shares · +265%
  3. Moonlake Immunotherapeutics MLTX+355,813 shares · +71%
  4. Ocuphire Pharma Inc. IRD+1.6 million shares · +507%
  5. Annexon Inc. ANNX+1.0 million shares · +40%
  6. Contineum Therapeutics Inc. CTNM+121,283 shares · +15%
  7. LB Pharmaceuticals Inc. LBRX+17,221 shares · +6%

Trimmed 9

  1. Amylyx Pharmaceuticals Inc. AMLX-1.1 million shares · -60%
  2. Nektar Therapeutics NKTR-141,453 shares · -45%
  3. Bright Minds Biosciences Inc. DRUG-110,397 shares · -50%
  4. Silence Therapeutics PLC SLN-570,489 shares · -56%
  5. Neurogene Inc. NGNE-147,820 shares · -30%
  6. Eliem Therapeutics Inc. CLYM-334,130 shares · -25%
  7. Promis Neurosciences Inc. PMN-285,252 shares · -77%
  8. Palisade Bio Inc. PALI-1.1 million shares · -33%

and 1 more in the table below

Sold out of 13

  1. Apogee Therapeutics Inc. APGE$31.5 million last quarter
  2. Kalvista Pharmaceuticals Inc. KALV$13.6 million last quarter
  3. Immunovant Inc. IMVT$13.6 million last quarter
  4. Jade Biosciences Inc. JBIO$13.6 million last quarter
  5. Zenas Biopharma Inc. ZBIO$10.2 million last quarter
  6. Compass Therapeutics Inc. CMPX$7.1 million last quarter
  7. Scynexis Inc. SCYX$6.9 million last quarter
  8. Context Therapeutics Inc. CNTX$5.9 million last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Vor Biopharma Inc. VOR1.7M$31.3 million7.37%-50.0K
Abivax SA ABVX204.3K$27.2 million6.41%new
Vera Therapeutics Inc. VERA600.8K$25.8 million6.07%+401.5K
Zura Bio Ltd ZURA4.2M$24.9 million5.86%no change
Alumis Inc. ALMS856.1K$24.1 million5.68%no change
Sol Gel Technologies SLGL274.4K$20.3 million4.79%no change
Definium Therapeutics Inc. DFTX425.0K$20.0 million4.71%new
Annexon Inc. ANNX3.5M$20.0 million4.71%+1.0M
Oruka Therapeutics Inc. ORKA183.3K$17.4 million4.11%no change
Moonlake Immunotherapeutics MLTX855.8K$16.7 million3.93%+355.8K
Sagimet Biosciences Inc. SGMT2.0M$15.7 million3.70%new
Contineum Therapeutics Inc. CTNM921.5K$15.1 million3.56%+121.3K
Immix Biopharma Inc. IMMX1.3M$13.2 million3.10%+927.6K
Eliem Therapeutics Inc. CLYM1.0M$13.0 million3.07%-334.1K
Amylyx Pharmaceuticals Inc. AMLX700.0K$12.6 million2.96%-1.1M
Nektar Therapeutics NKTR175.0K$12.2 million2.88%-141.5K
Neurogene Inc. NGNE352.2K$11.1 million2.61%-147.8K
LB Pharmaceuticals Inc. LBRX317.2K$10.3 million2.43%+17.2K
Ocuphire Pharma Inc. IRD2.0M$8.1 million1.91%+1.6M
Eupraxia Pharmaceuticals Inc. EPRX1.2M$7.9 million1.87%no change
Bright Minds Biosciences Inc. DRUG109.6K$7.7 million1.81%-110.4K
Inflarx NV IFRX3.0M$6.8 million1.61%new
Relmada Therapeutics Inc. RLMD842.1K$5.8 million1.37%no change
Jatt II Acquisition Corp. JATT500.0K$5.7 million1.34%new
Cullinan Therapeutics Inc. CGEM300.0K$5.5 million1.29%no change
Altimmune, Inc. (alt) ALT1.7M$5.3 million1.25%new
Amanat Acquisition Corp. AMAN500.0K$5.1 million1.20%new
Rezolute Inc. RZLT951.8K$4.9 million1.17%no change
Silence Therapeutics PLC SLN450.0K$4.9 million1.16%-570.5K
Palisade Bio Inc. PALI2.3M$4.8 million1.13%-1.1M
Evommune Inc. EVMN325.0K$4.3 million1.02%no change
Scynexis Inc. SCYX944.3K$3.8 million0.91%new
Enliven Therapeutics Inc. ELVN70.0K$3.6 million0.84%new
Humacyte Inc. HUMA3.8M$2.9 million0.69%no change
Aileron Therapeutics Inc. RNTX2.6M$2.7 million0.63%new
DBV Technologies S A DBVT156.9K$2.6 million0.61%new
Promis Neurosciences Inc. PMN86.2K$1.1 million0.27%-285.3K
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 13 it sold out of are in the box above.

Options it reported

CompanyOptionShares under the optionsValue of those shares
Abivax SA ABVXCalls400.0K$53.3 million
Immunitybio Inc. IBRXPuts3.0M$26.3 million
Ultragenyx Pharmaceutical in RAREPuts600.0K$20.0 million
Galectin Therapeutics Inc. GALTCalls800.0K$3.7 million
Anavex Life Sciences Corp. AVXLCalls521.3K$1.4 million

5 option lines. A 13F lists calls and puts by the shares they cover and what those shares were worth at the quarter's end, not what the options cost; they are not counted in the holdings above.